Second clinical candidate from HUTCHMED’s next-generation ATTC platform — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Investigators continue to seek more information on how to optimally integrate treatment with tyrosine kinase inhibitors (TKIs) into an established concurrent chemoradiotherapy regimen. New data from ...
Figure 6: Mechanism of Anti-EGFR resistance in head and neck cancer by activation of TLR4-MyD88 signaling. EGFR inhibition by cetuximab prevents Src activation, thus preventing MyD88 degradation, ...
February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...
February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...
HUTCHMED has initiated a global phase 1/2a clinical trial of HMPL‑A580, its second antibody‑targeted therapy conjugate, in ...
WILMINGTON, Del.--(BUSINESS WIRE)--Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with locally advanced or ...
Continuing anti-vascular endothelial growth factor (VEGF) therapy plus chemotherapy in the second-line setting led to a small but nonsignificant increase in overall survival in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results